Galantamine provides sustained benefits in patients with 'advanced moderate' Alzheimer's disease for at least 12 months

Dementia and Geriatric Cognitive Disorders

Volumn 15, Issue 2, 2003, Pages 79-87

  Blesa, Rafael ^a   Davidson, Michael ^b   Kurz, Alexander ^c   Reichman, William ^e   Van Baelen, Bart ^f   Schwalen, Susanne ^d  

^a HOSPITAL CLÍNIC   (Spain)

^b TEL AVIV UNIVERSITY   (Israel)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d JANSSEN CILAG GMBH   (Germany)

^e UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

^f SGS Medisearch International NV   (Belgium)

Author keywords

Advanced disease; Alzheimer's disease; Galantamine; Long term

Indexed keywords

GALANTAMINE; PLACEBO;

ABDOMINAL DISEASE; AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL TRIAL; COGNITION; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MEDICAL RECORD; MULTICENTER STUDY; NAUSEA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINITIS; SCALE UP; SCORING SYSTEM; SIDE EFFECT; VERTIGO; VOMITING; WEIGHT REDUCTION;

AGED; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; DOUBLE-BLIND METHOD; GALANTAMINE; HUMANS; PSYCHIATRIC STATUS RATING SCALES; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 0037236816     PISSN: 14208008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000067974     Document Type: Article

References (22)

1. Maelicke A: Allosteric modulation of nicotinic receptors as a treatment strategy for Alzheimer's disease. Dement Geriatr Cogn Disord 2000;11(suppl 1):11-18.
2. Rockwood K, Mintzer J, Truyen L, Wessel T, Wilkinson D, on behalf of the Galantamine International-2 Study Group: Effects of a flexible galantamine dose in Alzheimer's disease: A randomized, controlled trial. J Neurol Neurosurg Psychiatry 2001;71:589-595.
3. Tariot PN, Solomon PR, Morris JC, Kershaw P, Lilienfeld S, Ding C: A 5-month, randomized, placebo-controlled trial of galantamine in Alzheimer's disease: The Galantamine USA-10 Study Group. Neurology 2000;54:2269-2276.
4. Raskind MA, Peskind ER, Wessel T, Yuan W, on behalf of the Galantamine USA-1 Study Group: Galantamine in AD: A 6-month, randomized, placebo-controlled trial with a 6-month extension. Neurology 2000;54:2261-2268.
5. Wilcock GK, Lilienfeld S, Gaens E, on behalf of the Galantamine International-1 Study Group: Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: A multicentre randomised controlled trial. BMJ 2000;321:1445-1449.
6. Wessel T, Gaens E: The long-term cognitive benefits of galantamine treatment in patients with Alzheimer's disease (poster). 125th Annu Meet Am Neurol Assoc, Boston, October 2000.
7. Olin J, Schneider L: Galantamine for Alzheimer's disease (Cochrane Review). Cochrane Library, issue 2. Oxford, Update Software, 2001.
8. Davis KL, Mohs RC, Marin D, Purohit DP, Perl DP, Lanz M, Austin G, Haroutunian V: Cholinergic markers in elderly patients with early signs of Alzheimer's disease. JAMA 1999;281:1401-1406.
9. Feldman H, Sauter A, Donald A, Gelinas I, Gauthier S, Torfs K, Parys W, Mehnert A: The Disability Assessment for Dementia scale: A 12-month study of functional ability in mild to moderate severity Alzheimer disease. Alzheimer Dis Assoc Disord 2001;15:89-95.
10. National Institute for Clinical Excellence: Guidance on the Use of Donepezil, Rivastigmine and Galantamine for the Treatment of Alzheimer's Disease. Technology Appraisal Guidance No 19, January 2001.
11. Stern RG, Mohs RC, Davidson M, Schmeidler J, Silverman J, Kramer-Ginsberg E, Searcey T, Bierer L, Davis KL: A longitudinal study of Alzheimer's disease: Measurement, rate and predictors of cognitive deterioration. Am J Psychiatry 1994;151:390-396.
12. Torfs K, Feldman H: 12-month decline in cognitive and daily function in patients with mild-to-moderate Alzheimer's disease: Two randomized, placebo-controlled studies (poster). 7th Int World Alzheimer Congr, Washington, July 2000.
13. Rosen WG, Mohs RC, Davis KL: A new rating scale for Alzheimer's disease. Am J Psychiatry 1984;141:1356-1364.
14. Gelinas I, Gauthier L, McIntyre M, Gauthier S: Development of a functional measure for persons with Alzheimer's disease: The disability assessment for dementia. Am J Occup Ther 1999;53:471-481.
15. Galasko D, Bennett D, Sano M, Ernesto C, Thomas R, Grundman M, Ferris S: An inventory to assess activities of daily living for clinical trials in Alzheimer's disease: The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997;11(suppl 2):S33-S39.
16. Wilkinson D, Hock C, Farlow M, van Baelen B, Schwalen S: Galantamine provides broad benefits in patients with 'advanced moderate' Alzheimer's disease (MMSE ≤ 12) for up to 6 months. Int J Clin Pract, in press.
17. Wilkinson D, Schwalen S: Reminyl™ (galantamine) produces significant improvements in symptoms in patients with 'advanced moderate' Alzheimer's disease (poster). 10th Congr Int Psychogeriatr Assoc, Nice, September 2001.
18. Stahl S, Markowitz J, Gutterman E, Papadopoulos G: No increase in adverse sleep-related outcomes during double-blind trials with Reminyl™ (galantamine) in Alzheimer's disease (poster). 10th Congr Int Psychogeriatr Assoc, Nice, September 2001.
19. Stahl S, Markowitz J, Gutterman E: Aricept® (donepezil) is associated with increased hypnotic use among Alzheimer's disease patients living in the community (poster). 10th Congr Int Psychogeriatr Assoc, Nice, September 2001.
20. Rogers SL, Friedhoff LT: Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: An interim analysis of the results of a US multicentre open label extension study. Eur Neuropsychopharmacol 1998;8:67-75.
21. Rockwood K, Kershaw P: Galantamine's clinical benefits are not offset by sleep disturbance: A 3-month, placebo-controlled study in patients with Alzheimer's disease (poster). 7th Int World Alzheimer's Congr, Washington, July 2000.
22. Robillard A, McKelvey R, Nasreddine Z: Galantamine improves quality of sleep in patients previously treated with donepezil (preliminary results) (poster). 17th World Congr Neurol, London, June 2001.